



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : R. Vanlalsiama,
Asst Director (F&D),
CMO Office, Lunglei.
2. Serial No. and date of Inspector's memorandum : 8 Date 12/12/24
3. Number of Sample :MS-12
4. Date of receipt :23-DEC-2024
5. Names of drugs purporting to be contained in the sample: Cetirizine Tablets IP 10 mg

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024-25/1532	GUW/LS/2024-25/1552	EPD2AI2001	APR. 22	MAR. 25	IBN Herbals, Khasra No. 63, Vill.JuddiKalan, Baddi-173 205, Distt. Solan (H.P.), India.

6. Condition of seals on : Seals were intact & identical to the
 [the packet or on portion of sample or container] Specimen impression of the seal
 received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied :Please see below

Date of Testing : From 10-Jan-2025To 17-Jan-2025

COMPOSITION : Each film coated tablet contains:
 Cetirizine Hydrochloride IP 10 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, elongated, bi-convex, film coated tablet, one side scored, plain on the other side, packed in blister strip.	NA
2	Identification	Gives positive test for Cetirizine Hydrochloride.	NA
3	Average weight	0.14817 gm.	NA
4	Dissolution	Complies (Release of all six units found above 'Q' 75 +5%).	NLT 75 % of Claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cetirizine Hydrochloride	10.69 mg/Tablet	10 mg/Tablet	106.9	90 % to 110 %	I.P. 2022

In the opinion of the under signed the sample referred to above is of **standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 20-JAN-2025

GOVERNMENT ANALYST
Dilip Kr. Sarkar
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

